**Name of Journal: *World Journal of Respirology***

**ESPS Manuscript NO: 22849**

**Manuscript Type: Review**

**Lung cancer screening: Should we be excluding people with previous malignancy?**

Erkmen CP *et al*. Previous malignancy and lung cancer screening

**Cherie P Erkmen, Larry R Kaiser, Ashley L Ehret**

**Cherie P Erkmen**, **Larry H Kaiser**, Department of Thoracic Medicine and Surgery, Temple University Health System, Philadelphia, PA 19140, United States

**Ashley L Ehret**, Department of Surgery, Temple University Health System, Philadelphia, PA 19140, United States

**Author contributions:** Erkmen CP is the primary researcher and author of the manuscript; Ehret AL and Kaiser LH contributed to literature review, evaluation, analysis, writing, revising and formatting the manuscript.

**Conflict-of-interest statement*:*** Erkmen CP, Kaiser LH and Ehret AL have no conflicts of interest to disclose.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Correspondence to:** **Cherie P Erkmen, MD,** **Associate Professor** of Surgery, **Director** of The Temple-Fox Chase Lung Cancer Screening Program, Department of Thoracic Medicine and Surgery, Temple University Health System, 3401 North Broad Street, Philadelphia, PA 19140, United States. cherie.p.erkmen@tuhs.temple.edu

**Telephone:** +1-215-7079115

**Fax:** +1-215-70791131

**Received:** September 28, 2015

**Peer-review started:** September 28, 2015

**First decision:** November 30, 2015

**Revised:** January 19, 2016

**Accepted:** March 14, 2016

**Article in press:**

**Published online:**

**Abstract**

The National Lung Screening Trial (NLST) was a large, randomized, controlled study showing a 20% reduction of lung cancer mortality and 7% reduction of all cause mortality using annual low dose CT (LDCT) in a high risk population. NLST excluded people with a previous history of cancer treatment within the past 5 years and all people with a history lung cancer. The aim of this work is to review how lung cancer screening trials addressed the confounding effect of previous malignancy. We also review the subsequent recommendations by the United States Preventative Task Force Services, multiple professional societies and the Center for Medicaid and Medicare Services which defer either to NLST criteria or, clinician judgment or refrain from asserting any recommendation on the topic, respectively. Implications of lung cancer screening in the setting of previous malignancies, specifically lung, head and neck, esophageal, gastric, breast, colorectal cancer and lymphoma are also discussed. With lung cancer screening, an antecedent malignancy introduces the possibility of discovering metastasis as well as lung cancer. In some circumstances diagnosis and treatment of oligometastatic disease may confer a survival benefit. The survival benefit of treating either lung cancer or oligometastatic disease as result of lung cancer screening has yet to be determined. Further studies are needed to determine the role of lung cancer screening in the setting of previous malignancy.

**Key words:** Lung cancer screening; Criteria; Previous malignancy; Antecedent malignancy; Lung metastasis; Guidelines; Lung Cancer; Low dose computed tomography; Head and neck cancer; Esophageal cancer; Gastric cancer; Breast cancer; Colorectal cancer; Lymphoma

**© The Author(s) 2016.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Most lung cancer screening trials, including the National Lung Screening Trial, exclude those with a history of a previous malignancy as it may introduce confounding factors that influence survival. However, people with previous malignancy may benefit from the discovery of treatable lung cancer as well as treatable metastasis. In this review, we summarize the consideration that studies and national guidelines give in regards to lung cancer screening in patients with previous malignancy. Furthermore, we address the implications of lung cancer screening in the setting of specific malignancies, namely lung, head and neck, esophageal, gastric, breast, colorectal cancer and lymphoma.

Erkmen CP, Kaiser LH, Ehret AL. Lung cancer screening: Should we be excluding people with previous malignancy? *World J Respirol* 2016; In press

**INTRODUCTION**

According the National Cancer Institute, lung cancer is the most common cause of cancer death among both men and women, accounting for more deaths than breast, colorectal, prostate and pancreatic cancer combined. Nearly 75% of lung cancers are diagnosed at stage III or IV[1], thus contributing to the dismal average five-year survival of 17.4 to 18.5 percent[2,3]. Though early detection through lung cancer screening should be expected to confer a survival benefit, several studies have failed to prove this, even in large randomized trials[4]. In 2011, the National Lung Screening Trial (NLST) compared a low dose CT (LDCT) scan to chest radiography (CXR) as a modality of lung cancer screening. LDCT reduced the risk of lung cancer death by 20% and death from all causes by 7%[5]. This was a multi-institutional, randomized study of over 53000 patients. The NLST restricted eligibility to those with greater than 30 pack years of smoking, active smokers or those who quit smoking within the past 15 years who were between the ages of 55 to 74. In addition to including those at high risk of lung cancer, NLST excluded people who were not likely to benefit from lung cancer screening, namely those who were unwilling to undergo surgical resection, those with major health problems that would preclude lung cancer treatment, and those with obvious symptoms of lung cancer. The combination of a sufficiently powered study, inclusion of only those at highest risk of lung cancer and exclusion of people unlikely to benefit from early lung cancer detection contributed to the unprecedented mortality risk reduction of NLST. LDCT, applied to the US population could potentially avert 12,000 lung cancer deaths per year[6].

However, Pinsky *et al*[7] utilized data from Surveillance, Epidemiology and End Results (SEER), the United States Census and the National Health Interview Survey to determine that only 6.2% of the United States population over 40 years old was eligible for lung cancer screening. Additionally, only 26.7% of people with lung cancers would have been eligible for lung cancer screening by NLST criteria Farjah *et al*[8] used a risk-prediction model to review resected lung cancer patients. The authors concluded that NLST lung cancer screening criteria may exclude people who have a predicted risk greater than or equal to those who are currently eligible. Many people excluded by NLST criteria could benefit from lung cancer screening. This study prompts scrutiny of the exclusion criteria of lung cancer screening.

Looking at the design of NLST, is important to categorize the exclusion criteria into exclusion because people will not likely benefit from lung cancer screening, and exclusion that confounds a clinical trial. Patients presenting with symptoms of lung cancer such as, weight loss or, hemoptysis, and those who are unwilling to undergo lung cancer surgery are not likely to benefit from lung cancer screening[9]. However other NLST exclusion criteria such as “patients participating in another screening trial or cancer prevention study” may benefit from lung cancer screening, but were not included to avoid confounding scenarios. Similarly, the NLST exclusion of patients with metallic implants or devices in the chest or back, patients with a Chest CT within the past 18 mo, patients with a recent pneumonia or respiratory tract infection, or patients with removal of any portion of the lung excluding needle biopsy could all possibly benefit from the lung cancer mortality risk reduction of LDCT. More controversially, NLST excluded those on home oxygen and those with previous malignancy. Though unclear if these people will benefit from LDCT, they at least deserve further study.

**EXCLUSION OF PATIENTS WITH PREVIOUS MALIGNANCY**

NLST excluded people with a history of lung cancer and those who were treated for a malignancy within five years of the initial screen. People with non-melanomatous skin cancer were still eligible for lung cancer screening. From the perspective of study design, previous malignancy introduces confounding challenges to the study of lung cancer screening: (1) A lung nodule has a 40%-60% chance of being a metastasis from a previous malignancy. Radiologists may interpret a nodule differently with the knowledge of a previous malignancy[10,11]; (2) The management of a lung nodule in a patient with a previous cancer history varies from that in patients without a cancer history. For instance, a lung nodule in the setting of previous cancer may prompt a PET scan to look for other metastasis or recurrence of the primary cancer. The recommendation for management of the same nodule in a patient without previous malignancy may be a follow up CT scan. It is difficult to establish the benefit and harms of screening when work-up and treatment varies within the study group; (3) The etiology of a malignant nodule cannot always be determined. For instance, a squamous cell cancer found in the lung may be a lung primary or a metastasis from a head and neck cancer. Even immunohistochemistry and genetic analysis may not be able to distinguish the cancer’s origin; (4) Previous malignancy introduces wide variability in survival. The type, stage and disease free interval of a previous malignancy all influence overall survival. It would be difficult to interpret if screening for lung cancer with a LDCT improved survival in these patients; (5) It can be challenging to determine the contribution a lung cancer, another distinct malignancy or the combination of the two has on mortality.

Previous studies of lung cancer screening had similar concerns about including patients with previous malignancy. We have summarized findings of index trials in lung cancer screening in Table 1. In 1993, Henschke and colleagues concluded that CT screening for lung cancer detected disease at an earlier stage than CXR in their Early Lung Cancer Action Project (ELCAP)[12]. Patients with prior cancer were excluded from the study. The ongoing International I-ELCAP study continues to limit enrollment to people with no previous history of lung cancer[13]. The Dutch-Belgian Randomized Lung Cancer Screening Trial (NELSON) was a longitudinal, population-based study of 335441 people proved that lung cancer screening with CT scanning and a volumetric lung nodule management algorithm was feasible[14]. The NELSON trial excluded persons with current or past renal cancer, melanoma or breast cancer were not included, “because these tumors give rise to lung metastasis even after long follow up. People with lung cancer within 5 years of diagnosis, and lung cancer diagnosed greater than 5 years from randomization, but still undergoing treatment were also excluded[15]. The Detection and Screening of Early Lung Cancer with Novel Imaging Technology (DANTE) Trial published their results comparing lung cancer mortality in those undergoing LDCT compared to no screening in May of 2014[16]. Unlike NLST, there was no reduction in lung cancer or all cause mortality in 2532 patients randomized to LDCT *vs* no screening. Similar to NLST and NELSON, persons with a previous malignancy within 10 years of recruitment were ineligible. The Prostate, Lung, Colorectal, and Ovarian cancer screening trial was a population study of over 154000 patients looking at lung cancer death as a primary outcome[17]. There was no reported difference in lung cancer mortality with CXR as a screening modality[4,18]. This study excluded patients with prior cancer of the colon, rectum, lung, prostate, ovary or individuals undergoing treatment for cancer at the time of the study, excluding basal-cell and squamous-cell skin cancer.

At the time of this writing, 15 studies of lung cancer screening are registered as “active” with ClinicalTrials.gov. Of these 15 studies, 13 have exclusion criteria for people with a history of previous malignancy, including lung cancer. These studies have varying exceptions, but all allowed people with non-melanomatous skin cancer to be eligible for lung cancer screening. Only two studies made no mention of excluding people with previous malignancy. Only one study aims to look at lung cancer screening in the setting of previous malignancy, namely Hodgkin’s Lymphoma[19].

**RECOMMENDATIONS FOR LUNG CANCER SCREENING**

Though the exclusion of a previous malignancy makes sense in the setting of a randomized trial, it does not necessarily translate to the logic of excluding these patients as a policy. In 2014, the United States Preventative Services Task Force (USPSTF) updated their recommendations regarding lung cancer screening[20]. The previous recommendation, published in 2004, found insufficient evidence to recommend LDCT for lung cancer screening. With compelling evidence from four randomized controlled studies (NLST, DANTE (Detection and Screening of Early Lung Cancer by Novel Imaging Technology and Molecular Essays)[13,21], DLCST (Danish Lung Cancer Screening Trial)[22], and MILD (Multicentric Italian Lung Detection)[23] the USPSTF “concludes with moderate certainty that annual screening for lung cancer with LDCT is of moderate net benefit[16].”

Interestingly, USPSTF departed from the NSLT in its recommendations by expanding eligibility. Based on comparative modeling studies calibrated to both NLST and Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial data, de Koning *et al*[24] found that annual LDCT has a favorable benefit-harm ratio for individuals aged 55 through 80, not 55 to 74 as defined by NLST. USPSTF does not mention excluding people with a history of previous malignancy. Even though both NLST and PLCO had exclusion criteria of lung cancer and restrictions on any previous malignancy, USPSTF did not recommend including or excluding people with previous malignancy from lung cancer screening. This leaves clinicians to interpret the USPSTF recommendation to screen patients in a fashion “similar to NLST”.

The American Lung Association (ALA) in 2012 published guidance on lung cancer screening addressing both patients and physicians in 2012[25]. Though the ALA did not specifically address screening people with previous malignancy, they did acknowledge that lung cancer screening requires future refinement of the criteria. In the absence of randomized control data for all clinical scenarios of criteria, they suggest relying on risk stratification models. They cite Tammemagi and colleagues’ use of PLCO participants to develop a lung cancer risk prediction model[26] which performed better than the NLST criteria. Unfortunately, risk prediction models rely on existing data about lung cancer screening, which excludes those with a history of previous malignancy.

The American College of Chest Physicians (ACCP) released their evidence-based clinical practice guidelines in 2013[27]. Regarding the inclusion and exclusion criteria of the NLST, the authors state, “Expanding screening to cohorts other than those included in the NLST is probably not warranted at this time unless it is in the context of a research study.” They also look to risk prediction models to assist with establishing screening criteria, however they must account for competing causes of death. More specifically, for those with a previous malignancy, further studies are needed to understand how a previous malignancy impacts lung cancer death. Though there are no clear recommendations about lung cancer screening in those with previous malignancy, the ACCP and their collaborative, multi-society statement with the American Cancer Society (ACS), the American Society of Clinical Oncology (ASCO) and the NCCN emphasizes the need to balance the benefits and harms of lung cancer screening on an individual basis[28].

The Centers for Medicare and Medicaid Services released their final national coverage determination for lung cancer screening with LDCT in February of 2015[29]. The supporting data cites the Cochrane Database Systematic Review[30] and a systematic review by Prosch and Schaefer-Prokop[31]. Both of these reviews included studies like NLST, DANTE, DLCST and PLCO which all excluded people with previous malignancy. However there is no recommendation on either including or excluding patients with previous malignancy.

In the 2015 review of current American Cancer Society (ACS) guidelines for cancer screening in the United States, the authors advise that clinicians should initiate a discussion about lung cancer screening in people who meet the criteria of the NLST. “Clinicians should not discuss LDCT lung cancer screening with patients who do not meet the recommended criteria,” including those with previous malignancy. The ACS allows for judgment of the clinician to discuss lung cancer screening when the risk “seems to approximate” NSLT eligibility criteria. They note that the uncertainty of harms and benefits outside the NLST criteria are too great to recommend screening.

In contrast, in the most recent 2015 update of the National Comprehensive Cancer Network (NCCN) guidelines for lung cancer screening[32], the panel members do not exclude patients with previous cancer from lung cancer screening. In fact, the NCCN guidelines include a personal cancer history as a significant risk factor for developing lung cancer. The guidelines highlight that those who survive lung cancer, lymphomas, cancers of the head and neck and other smoking-related cancers such as esophageal cancer. The panel recommends that with one additional risk factor (category 2A), like previous malignancy, lung disease, family history of lung cancer, radon exposure and occupational exposure to carcinogens, individuals aged 50 or older with a 20 pack-year history of smoking tobacco should undergo lung cancer screening.

The most comprehensive evaluation of lung cancer screening in patients with previous malignancy is found in the American Association for Thoracic Surgery guidelines[33]. These guidelines note that people with previous cancer, lung cancer in particular, are at increased risk of developing a lung malignancy. Complex environmental and genetic factors that predispose someone to the first malignancy are still relevant for the development of a second lung cancer. Additionally, treatment with radiation therapy or alkylating agents for a previous cancer may also contribute to the risk of developing lung cancer. The consensus opinion is that a previous malignancy should not exclude patients from lung cancer screening. Furthermore, a previous malignancy is an indication to start lung cancer screening at an earlier age and in those with less tobacco exposure than currently recommended by NLST criteria. With regard to patients who have been successfully treated for lung cancer, they should receive high resolution CT scans for 4 years followed by annual LDCT screening for the rest of their life, or until functional status or refusal to undergo lung cancer treatment precludes the potential benefit of lung cancer screening. Jaklitsch *et al*[33] recommend lung cancer screening in patients with level 2 evidence (*i.e.,* data from case-controlled or nonrandomized clinical trials).

 In the absence of specific data about lung cancer screening in the setting of previous malignancy, risk prediction models can guide recommendations. Tammemagi *et al*[26] have developed a lung cancer risk prediction model ([www.brocku.ca/lung-cancer-risk-calculator](http://www.brocku.ca/lung-cancer-risk-calculator)). This model incorporates multiple variables including smoking (intensity, duration, quit time), social circumstances and personal health history[34,35]. Selecting individuals for lung cancer screening based on accurate lung cancer risk prediction models can increase sensitivity (83.0% *vs* 71.1%; *P* < 0.001) and positive predictive value (4.0% *vs* 3.4%; *P* = 0.01) without loss of specificity (62.9% and 62.7%; *P* = 0.54) compared to NLST or USPSTF criteria[36]. Accurate modeling can lead to smaller numbers of individuals being screened, identification of more lung cancers and an increased positive predictive value[37]. Early data of lung cancer screening in patients with antecedent malignancy suggests that such screening may contribute to developing personalized risk prediction models.

**LUNG CANCER SCREENING IN PATIENTS WITH HISTORY OF SPECIFIC MALIGNANCY**

The benefit that lung cancer screening can confer on a patient with previous malignancy depends on the antecedent cancer. Benefit may be in the form of finding lung cancer in a high risk population, or in the form of finding treatable metastasis. We summarize the existing knowledge of lung cancer screening in the setting of previous lung, head and neck, esophageal, gastric, breast, colorectal cancer and lymphoma (Table 2).

***Lung cancer***

A history of lung cancer is one of the strongest risk factors for developing a new lung cancer. In a study of 1294 patients undergoing resection for early stage lung cancer, 7% presented with a second primary lung cancer within a median follow up of 35 mo [38]. People with lung cancer have a 3%-6% risk per year of developing a second lung cancer, a risk that actually increases with time[31,39,40]. This increased risk of a second lung cancer persists to even 10 years after the initial diagnosis[41]. By comparison, in the NLST high-risk population, the incidence of lung cancers was less than 1% per patient year[5]. Screening lung cancer patients should be at least as successful in discovering a new lung cancer as screening those who fit the NLST criteria. Second primary lung cancers found during surveillance are diagnosed in stage I (92%) or stage II (4%), suggesting a survival benefit[31]. However, the survival benefit of long term, annual LDCT to screen for second primary lung cancers is unknown. Special consideration should be given to the possibility of false positives (25%) and unnecessary invasive procedures (3%) and complications from unnecessary invasive procedures (0.3%) from nodules found in the setting of CT scanning after lung cancer treatment[31].

Surveillance following the treatment of lung cancer consists of a history and physical and chest CT every 6 to 12 mo for two years, then a history and physical with a LDCT annually, according to NCCN guidelines[31]. Locoregional recurrence occurs in 10%-30% of patients[42], and metastatic spread occurs in 15-39% of patients[33]. A majority of these occur within the first 2 years of diagnosis[43]. For the first 4 years after surgery, the risk of recurrence is 6% to 10% per patient year but decreases thereafter to 2%[31]. In a review of 9 studies looking at lung cancer recurrence following surgical resection[44], Mollberg *et al*[44] found that only 0.9% to 4.4% of patients with lung cancer recurrence were candidates for repeated resection. A more recent study by Crabtree *et al*[45] showed that 40%-41% of subsequent malignancies were treated with curative intent. Data on five-year survival following recurrence varies widely from 8.3% to 40.0% with improved survival in those receiving curative treatment[37,38]. Though it would seem that early detection of recurrent lung cancer would improve survival, several studies comparing intense surveillance for lung cancer with clinic visits and CT scans failed to demonstrate a survival benefit[38,46]. A randomized trial in France comparing lung cancer surveillance with CXR *vs* CT and bronchoscopy is underway. Hopefully these results will clarify which surveillance techniques improve survival[47]. Regardless of whether a CT following lung cancer treatment is for surveillance for recurrence or early diagnosis of a new lung cancer, the impact on survival is still unclear. Advances in targeted therapy, novel chemotherapeutic regimens and palliative care give promise toward improved survival, even with a diagnosis of metastatic disease.

Perhaps the greatest value of surveillance and screening in lung cancer survivors is ensuring that patients are smoke free. Parsons and colleagues found that continued smoking following treatment for lung cancer was associated with a significant increased risk of recurrence and an almost threefold increase risk of all cause mortality[48]. Even recent quitters enjoy a significant improvement in disease free and overall survival compared to those who continue to smoke[49]. Smoking cessation confers a benefit for lung cancer patients at any time.

***Head and neck cancer***

Head and neck cancer and lung cancer share the risk factors of smoking and age. Up to 15%-20% of head and neck cancer patients develop a second primary malignancy[50]. Lung cancer accounts for 50% of these second primary malignancies and 50% of second primary malignancy-related deaths in patients with head and neck cancer[51]. With proactive follow up with a CT scan, oro-nasopharyngeal and esophageal endoscopy, Wolf and colleagues found a second primary malignancy in 18% of head and neck squamous cell cancer (HNSCC) patients[52]. Almost half of the second primary malignancies turned out to be primary lung cancer. Of the patients found to have a second primary malignancy, 86% were diagnosed at an early stage and were able to undergo therapy with curative intent. Though this study demonstrated that a lung cancer can be found and treated in patients with head and neck cancer, they did not study the influence of lung cancer treatment on survival.

To date, there are no controlled trials of head and neck cancer patients comparing survival with and without LDCT screening for lung cancer. In the absence of controlled trials, a recent survey of Canadian Head and Neck Surgeons showed that a majority of surgeons believe lung screening can improve patient mortality, and 31% currently screen high-risk patients for lung cancer with a LDCT[53]. However, Pagedar *et al*[54] found that the median survival of patients with lung cancer was 38 mo compared to 22 mo in patients with an antecedent history of head and neck cancer. These authors suggest that screening patients with a history of head and neck cancer with LDCT may not have the same survival benefit as those without this cancer history.

Additional questions arise when screening head and neck cancer patients for lung cancer. For instance, it is not always possible to determine if a pulmonary nodule is a primary lung cancer or a metastasis. Previously, Geurts *et al*[55] found that there is no difference in overall survival between patients who had surgical resection of a metastasis *vs* a lung cancer[55]. This would argue for screening in the setting of head and neck cancer. However a directed study looking at survival in the setting of screening has yet to be done. As second question is when to start screening head and neck cancer patients, at the time of diagnosis or some interval following successful treatment? Patients presenting with synchronous second primary lung cancer are more likely to have treatable, early-stage disease, as compared to patients with metachronous malignancy[56]. Five-year survival is higher in patients with synchronous head and neck and lung cancer compared to metachronous malignancies[57]. The improved 5-year survival is likely due to increased detection of early stage disease and earlier intervention. It is possible that lung cancer screening may aid in detecting metachronous malignancy at an earlier stage and thus may improve survival, but this is yet to be demonstrated in the literature. These questions and controversies will hopefully lead to controlled trials looking at lung cancer screening in the setting of head and neck cancer. Clinicians must evaluate the value of lung cancer screening in head and neck cancer survivors on an individual basis, taking into consideration the patient’s expected survival, risk of lung cancer, and potential benefit of treatment for either lung primary or metastasis. As with all cancer patients with a smoking history, a discussion of lung cancer screening should also include a discussion about smoking cessation.

***Esophageal cancer and gastric cancer***

Patients with esophageal cancer, gastric cancer and lung cancer share smoking as a common risk factor. In a study of 116 consecutive cases of esophageal cancer, 19% had a solitary pulmonary nodule[58]. Of these, 68% were benign nodules, 18% were new primary lung cancers and none were metastatic esophageal cancer. In patients with gastric cancer, 9.2% had secondary primary malignancies, of which lung was the most common (18.4%)[59]. In this same study, logistic regression analysis failed to show a significant association between age, gender, smoking, alcohol and H. pylori infection and the development of a second primary malignancy. The authors propose that clinicians consider the possibility for secondary primary malignancies during diagnosis and surveillance. However, there are no studies addressing the value of lung cancer screening. Furthermore, there are no evidence-based guidelines on who to screen and when to screen for lung cancer in those with previous esophageal and gastric cancer. Clinicians have to judge on an individual basis if the risk of lung cancer is great enough to screen, and if treatment of a discovered lung cancer will favorably impact survival. In sharing this decision with active smokers, clinicians must emphasize that risk reduction achieved by smoking cessation will likely surpass any risk reduction from lung cancer screening.

***Breast cancer***

Breast cancer is the most commonly diagnosed malignancy in females. Current recommendations in breast cancer surveillance recommend frequent physical exams and post-treatment yearly mammograms[60]. Given the rarity of lung metastasis, the American Society of Clinical Oncology guidelines do not recommend routine CT screening for metastatic disease of the lung[61]. Even during initial breast cancer workup, routine use of CT staging is thought to have limited value, low sensitivity, and considerable rate of false positives, and thus is recommended only in the setting of symptoms concerning for distal metastases[62]. However, excluding women with a history of breast cancer from LDCT lung cancer screening eliminates a large number of women who may otherwise benefit from early detection of malignancy. Almost 4% of breast cancer patients have pulmonary lesions during workup or identified during follow up[63]. In addition, while radiation therapy is an effective treatment for breast malignancy, it leads to a well-documented increase in risk for second primary malignancy of the lung[64,65]. This risk of treatment related lung cancer is significantly higher in patients with a smoking history[66].

Earlier diagnosis of lung cancer in a patient with a history of breast cancer carries an improved prognosis. Kerendi *et al*[67] reviewed the records of 35 patients with known breast cancer found to have a second primary malignancy of the lung[67]. Of these patients 54% were asymptomatic at the time of diagnoses, and the malignancy was found during workup or routine follow up. Pre-operative biopsy yielded a diagnosis in 82% of cases and 54% of these lung cancers were successfully treated with surgery. They documented an improved prognosis if the lung cancer was diagnosed when the patient was asymptomatic and if the patient was a non-smoker. In addition, it has been demonstrated that treatment of non-small cell lung cancer in the setting of a history of breast cancer paradoxically may convey an improved prognosis compared to patients diagnosed with non-small cell lung cancer alone. Data gathered from the SEER-18 registry indicated that non-small cell lung cancer was diagnosed at an earlier stage in patients with a breast cancer history, and these patients were more likely to undergo surgical resection[68]. Breast cancer history did not affect overall survival in local disease, but portended an improved overall survival in regional or distant lung cancer. Thus, it appears as though this patient population would certainly be ideal for inclusion in a LDCT lung cancer screening program.

While CT screening may identify a solitary pulmonary nodule, it is notoriously difficult to distinguish between primary lung malignancy and breast metastasis radiologically. Evidence suggests that over 50% of solitary pulmonary nodules detected in the setting of treated breast malignancy are primary lung cancer[69]. Kinoshita *et al*[70] reviewed records of 64 breast cancer patients who had undergone surgical resection of a pulmonary nodule. Of these, 37 patients (58%) were found to have a primary lung cancer. Retrospectively reviewing pre-operative CT scans after surgical diagnosis suggested that primary lung malignancy was significantly associated with the following radiologic findings: air bronchograms, increased size, and ill defined nodule border. However, these can still be non-specific findings and radiologic diagnosis continues to be a challenge.

This begs the question, does survival differ between patients with a solitary pulmonary nodule found to be lung cancer *vs* breast metastasis? Tanaka *et al*[69] studied 30 patients who underwent surgical resection for a solitary pulmonary nodule after curative surgery for breast cancer. They found that 93% of pulmonary nodules were malignant, 67% of these being primary lung cancer. Five-year survival after surgical resection was 100% in cases of breast metastasis and 61% in cases of primary lung cancer[62]. In another study, 84% of patients found to have a solitary breast cancer metastasis to the lung were able to undergo complete metastatic resection[71]. Thus, in the setting of a history of breast cancer a SPN is almost uniformly malignant. Again, given high 5-year survival rates regardless of pathologic diagnosis, LDCT screening is likely to be beneficial in breast cancer survivors who meet all other NLST criteria.

***Bladder cancer***

Lung cancer also shares an association with bladder cancer. A recent study examined 231 patients with non-muscle-invasive bladder cancer and found that 4% of these patients were found to have a second primary lung malignancy during follow up, a rate 10-fold higher than the local population[72]. Of those found to have a lung malignancy, 9 were found at late stage and only 1 was found at an early stage. In the 5 years following diagnosis, all patients with late stage lung cancer died; however the patient with early stage lung cancer was still alive after undergoing chemotherapy. In those patients with both primary lung and primary bladder cancer, the cause of death was uniformly attributed to lung cancer. Thus, the authors suggest early detection of a primary lung malignancy in a patient with history of non-invasive bladder cancer may contribute to improved survival. People with a history of bladder cancer who otherwise meet all other NLST criteria are likely to benefit from a discussion of lung cancer screening and smoking cessation, if applicable.

***Lymphoma***

Hodgkin’s Lymphoma is associated with a significantly increased risk of treatment related lung cancer. According to American College of Radiology (ACR) recommendations within the first 5 years of follow up, the imaging goal is to detect lymphoma recurrence. After this time the focus shifts towards detecting complications of treatment. The current ACR recommendations state that after 5 years there is no longer a need for follow up imaging, although mammography and low dose CT can be considered despite a lack of evidence of their benefit[73]. The incidence of lung cancer in patients with a history of Hodgkin’s Lymphoma is over 1% by 15 year follow up, with a relative risk of 4.62 (CI: 3.18-6.70)[74]. The risk is greater in patients diagnosed and treated for Hodgkin’s Lymphoma at an earlier age, especially 15-24.

Das *et al*[75] performed a cost-effectiveness estimate of annual lung cancer screening in patients with Hodgkin’s Lymphoma. Hypothetical patients for the model analysis were diagnosed with stage IA-IIB Hodgkin's lymphoma at age 25, with screening starting 5 years after initial diagnosis. Annual CT screening was predicted to increase survival by 0.64 years for smokers and 0.16 years for non-smokers, with improvement in quality of life and cost effectiveness greater in the population of smokers with lymphoma. Wattson *et al*[76] reported similar cost and survival benefits in smokers compared to non-smokers with Hodgkin’s Lymphoma. While non-smokers were predicted to experience a slightly improved survival and quality of life, LDCT scanning does not appear to be cost effective in this population.

In clinical practice it is unclear if this survival benefit of lung cancer screening is observed. Milano *et al*[77] examined overall survival in patients with Hodgkin’s Lymphoma diagnosed with NSCLC compared to controls diagnosed with only NSCLC. Lung cancer stage at diagnosis did not differ significantly between the groups. Despite this, Hodgkin’s Lymphoma survivors had a 30%-60% decrease in overall survival. This suggests that annual LDCT lung cancer screening may aid in identifying a second lung malignancy in this high-risk population, especially in current or heavy smokers. However, lung cancer screening may not provide as robust of a survival benefit in patients with a history of Hodgkin’s Lymphoma compared to the general population. There is currently a trial looking at lung cancer screening in people with a history of Hodgkin’s Lymphoma, which is expected to conclude by 2015[78]. Hopefully these results will define the benefit of lung cancer screening in this population.

***Colorectal cancer***

Low-dose CT may have a role in both colon cancer surveillance and screening for lung cancer. There have been many studies of postoperative surveillance programs following surgical resection of colon cancer. Aside from screening colonoscopy and CEA testing, there is little consensus opinion on the use of additional modalities that may detect colorectal cancer recurrence[79]. The purpose of these surveillance programs is to detect asymptomatic recurrences so intervention may occur at an earlier stage. A meta-analysis of 11 studies looking at intensity of surveillance determined that overall survival was significantly improved in patients who underwent more intense follow up (more frequent, additional imaging modalities). CT scanning of the pelvis and frequently the chest, lead to improved overall survival[80]. Thus, while not currently part of the surveillance guidelines, patients with a history of colorectal cancer would likely benefit from more frequent imaging of the chest.

Additionally, patients with colorectal cancer are more likely to be diagnosed with a primary lung cancer then the general population[81]. There is no difference between lung cancer incidence in patients with a history of colon or a history of rectal cancer[73]. A recent multicenter study in Japan examined whether a history of surgically resected colorectal cancer affected prognosis in patients diagnosed with lung cancer[34]. They compared 123 lung cancer patients with a history of colorectal cancer to 4431 controls with lung cancer alone. Patients with a history of colorectal cancer were more likely to be diagnosed at Stage IA, however there was no difference between the groups in overall survival or lung cancer mortality. This relationship did not vary with colorectal cancer stage. Thus, a previous history of surgically resectable colon cancer does not portend an improved nor diminished overall survival in patients diagnosed with a primary lung malignancy. These patients may still benefit from LDCT screening similar to the general population, so long as they fulfill all other accepted criteria for lung cancer screening. As with the majority of the previous malignancies discussed, there is a great need for prospective studies to examine clinical disease features, treatment response, and overall survival in these patients after lung cancer is detected by screening exam.

**CONCLUSION**

NLST demonstrated a reduction of lung cancer mortality and all cause mortality with annual screening LDCT. With regard to lung cancer screening in people with previous cancer, there is no data, as most lung cancer screening trials have excluded this population. Implementation of LDCT in the general population has proven complicated as USPSTF, professional societies and CMS have published slightly different recommendations on this and other criteria. The potential benefit of diagnosing early stage lung cancer or treatable metastatic disease is at least compelling enough to justify future study. Future directions include defining which malignancies at which stage are likely to benefit. The type of screening (routine CT dose or low dose), the interval of screening, and when to initiate and end screening after previous cancer treatment remain unanswered questions.

Until randomized, controlled studies can direct recommendations on lung cancer screening for people with antecedent malignancy, clinicians will need to consider screening on an individual basis. To be eligible for lung cancer screening, patients with previous malignancy should at least fulfill other lung cancer screening eligibility criteria. The previous malignancy, like any comorbidity, “should not substantially limit life expectancy or the ability or willingness to have curative (lung cancer) surgery” as defined by USPSTF. The prediction of survival benefit of lung cancer treatment and metastatic cancer treatment should outweigh the risks of screening. Clinicians should have a detailed, personalized discussion about these survival benefits of annual LDCT, as wells as the risks of false positive, overdiagnosis, anxiety, radiation, and the possibility what we know from all existing data may be insufficient to guide any individual decision. As with all lung cancer screening LDCT, a shared decision making tool should be used to address the issues of lung cancer screening that matter most to the individual. As patients with previous malignancy present complex scenarios, screening should be done within a setting with access to multidisciplinary evaluation and treatment. Most importantly, lung cancer screening in the setting of previous malignancy should include a discussion of smoking cessation in active smokers and a discussion with previous smokers of staying smoke free. Smoking cessation is critical in this population as these patients face the increased risk of recurrence, metastasis as well as lung cancer. When available, lung cancer screening of patients with previous malignancy should be done within a clinical trial.

In conclusion, though patients with previous malignancy have been excluded from lung cancer screening trials, they are a unique population that may enjoy a survival benefit from diagnosis of not only lung cancer, but of metastatic disease. Hopefully future clinical studies in this population will clarify the risks and benefits of lung cancer screening in the setting of antecedent malignancy.

**REFERENCES**

1 **Siegel R**, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. *CA Cancer J Clin* 2011; **61**: 212-236 [PMID: 21685461 DOI: 10.3322/caac.20121]

2 **Centers for Disease Control**. Unites States Cancer Statistics: Cancer Survival Data. [accessed 2015 Sept]. Available from: URL: http//nccd.cdc.gov/uscs/SurvivalData.aspx

3 **National Cancer Institute**. Surveillance, epidemiology and end results program: Lung and bronchus cancer facts sheet. [accessed 2015 Sept]. Available from: URL: http//seer.cancer.gov/statfacts/html/lungb.html

4 **Prorok PC**, Andriole GL, Bresalier RS, Buys SS, Chia D, Crawford ED, Fogel R, Gelmann EP, Gilbert F, Hasson MA, Hayes RB, Johnson CC, Mandel JS, Oberman A, O'Brien B, Oken MM, Rafla S, Reding D, Rutt W, Weissfeld JL, Yokochi L, Gohagan JK. Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. *Control Clin Trials* 2000; **21**: 273S-309S [PMID: 11189684 DOI: 10.1016/S0197-2456(00)00098-2]

5 **Aberle DR**, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, Gareen IF, Gatsonis C, Marcus PM, Sicks JD. Reduced lung-cancer mortality with low-dose computed tomographic screening. *N Engl J Med* 2011; **365**: 395-409 [PMID: 21714641 DOI: 10.1056/NEJMoa1102873]

6 **Ma J**, Ward EM, Smith R, Jemal A. Annual number of lung cancer deaths potentially avertable by screening in the United States. *Cancer* 2013; **119**: 1381-1385 [PMID: 23440730 DOI: 10.1002/cncr.27813]

7 **Pinsky PF**, Berg CD. Applying the National Lung Screening Trial eligibility criteria to the US population: what percent of the population and of incident lung cancers would be covered? *J Med Screen* 2012; **19**: 154-156 [PMID: 23060474 DOI: 10.1258/jms.2012.012010]

8 **Farjah F**, Wood DE, Zadworny ME, Rusch VW, Rizk NP. Resected Lung Cancer Patients Who Would and Would Not Have Met Screening Criteria. *Ann Thorac Surg* 2016; **101**: 274-279 [PMID: 26298169 DOI: 10.1016/j.athoracsur.2015.06.010]

9 **Aberle DR**, Berg CD, Black WC, Church TR, Fagerstrom RM, Galen B, Gareen IF, Gatsonis C, Goldin J, Gohagan JK, Hillman B, Jaffe C, Kramer BS, Lynch D, Marcus PM, Schnall M, Sullivan DC, Sullivan D, Zylak CJ. The National Lung Screening Trial: overview and study design. *Radiology* 2011; **258**: 243-253 [PMID: 21045183 DOI: 10.1148/radiol.10091808]

10 **Mery CM**, Pappas AN, Bueno R, Mentzer SJ, Lukanich JM, Sugarbaker DJ, Jaklitsch MT. Relationship between a history of antecedent cancer and the probability of malignancy for a solitary pulmonary nodule. *Chest* 2004; **125**: 2175-2181 [PMID: 15189939]

11 **Rena O**, Davoli F, Boldorini R, Roncon A, Baietto G, Papalia E, Turello D, Massera F, Casadio C. The solitary pulmonary nodule in patients with previous cancer history: results of surgical treatment. *Eur J Surg Oncol* 2013; **39**: 1248-1253 [PMID: 24035503 DOI: 10.1016/j.ejso.2013.08.014]

12 **Henschke CI**, McCauley DI, Yankelevitz DF, Naidich DP, McGuinness G, Miettinen OS, Libby D, Pasmantier M, Koizumi J, Altorki N, Smith JP. Early lung cancer action project: a summary of the findings on baseline screening. *Oncologist* 2001; **6**: 147-152 [PMID: 11306726 DOI: 10.1634/theoncologist.6-2-147]

13 **University Health Network Toronto**. Lung cancer screening in high-risk smokers using low-dose computed tomography. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). 2000-2015. Available from: URL: http//clinicaltrials.gov/ct2/show/NCT00188734?term=elcap&rank=2 NLM Identifier: NCT00188734

14 **van Iersel CA**, de Koning HJ, Draisma G, Mali WP, Scholten ET, Nackaerts K, Prokop M, Habbema JD, Oudkerk M, van Klaveren RJ. Risk-based selection from the general population in a screening trial: selection criteria, recruitment and power for the Dutch-Belgian randomised lung cancer multi-slice CT screening trial (NELSON). *Int J Cancer* 2007; **120**: 868-874 [PMID: 17131307 DOI: 10.1002/ijc.22134]

15 **van Klaveren RJ**, Oudkerk M, Prokop M, Scholten ET, Nackaerts K, Vernhout R, van Iersel CA, van den Bergh KA, van 't Westeinde S, van der Aalst C, Thunnissen E, Xu DM, Wang Y, Zhao Y, Gietema HA, de Hoop BJ, Groen HJ, de Bock GH, van Ooijen P, Weenink C, Verschakelen J, Lammers JW, Timens W, Willebrand D, Vink A, Mali W, de Koning HJ. Management of lung nodules detected by volume CT scanning. *N Engl J Med* 2009; **361**: 2221-2229 [PMID: 19955524 DOI: 10.1056/NEJMoa0906085]

16 **Infante M**, Lutman FR, Cavuto S, Brambilla G, Chiesa G, Passera E, Angeli E, Chiarenza M, Aranzulla G, Cariboni U, Alloisio M, Incarbone M, Testori A, Destro A, Cappuzzo F, Roncalli M, Santoro A, Ravasi G. Lung cancer screening with spiral CT: baseline results of the randomized DANTE trial. *Lung Cancer* 2008; **59**: 355-363 [PMID: 17936405 DOI: 10.1016/j.lungcan.2007.08.040]

17 **National Cancer Institute**. Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). 2000-2015. Available from: URL: http//clinicaltrials.gov/ct2/show/study/NCT01696968?term=plco lung&rank=1§=X3457016 NLM Identifier: NCT01696968

18 **Oken MM**, Hocking WG, Kvale PA, Andriole GL, Buys SS, Church TR, Crawford ED, Fouad MN, Isaacs C, Reding DJ, Weissfeld JL, Yokochi LA, O'Brien B, Ragard LR, Rathmell JM, Riley TL, Wright P, Caparaso N, Hu P, Izmirlian G, Pinsky PF, Prorok PC, Kramer BS, Miller AB, Gohagan JK, Berg CD. Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial. *JAMA* 2011; **306**: 1865-1873 [PMID: 22031728 DOI: 10.1001/jama.2011.1591]

19 **University Health Network Toronto**. Low dose chest CT for lung cancer screening in survivors of Hodgkin's disease. In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). 2000-2015. Available from: URL: http//clinicaltrials.gov/ct2/show/NCT01180010?term=lung cancer screening&rank=18 NLM Indentifier: NCT01180010

20 **Humphrey LL**, Deffebach M, Pappas M, Baumann C, Artis K, Mitchell JP, Zakher B, Fu R, Slatore CG. Screening for lung cancer with low-dose computed tomography: a systematic review to update the US Preventive services task force recommendation. *Ann Intern Med* 2013; **159**: 411-420 [PMID: 23897166 DOI: 10.7326/0003-4819-159-6-201309170-00690]

21 **Infante M**, Cavuto S, Lutman FR, Brambilla G, Chiesa G, Ceresoli G, Passera E, Angeli E, Chiarenza M, Aranzulla G, Cariboni U, Errico V, Inzirillo F, Bottoni E, Voulaz E, Alloisio M, Destro A, Roncalli M, Santoro A, Ravasi G. A randomized study of lung cancer screening with spiral computed tomography: three-year results from the DANTE trial. *Am J Respir Crit Care Med* 2009; **180**: 445-453 [PMID: 19520905 DOI: 10.1164/rccm.200901-0076OC]

22 **Saghir Z**, Dirksen A, Ashraf H, Bach KS, Brodersen J, Clementsen PF, Døssing M, Hansen H, Kofoed KF, Larsen KR, Mortensen J, Rasmussen JF, Seersholm N, Skov BG, Thorsen H, Tønnesen P, Pedersen JH. CT screening for lung cancer brings forward early disease. The randomised Danish Lung Cancer Screening Trial: status after five annual screening rounds with low-dose CT. *Thorax* 2012; **67**: 296-301 [PMID: 22286927 DOI: 10.1136/thoraxjnl-2011-200736]

23 **Pastorino U**, Rossi M, Rosato V, Marchianò A, Sverzellati N, Morosi C, Fabbri A, Galeone C, Negri E, Sozzi G, Pelosi G, La Vecchia C. Annual or biennial CT screening versus observation in heavy smokers: 5-year results of the MILD trial. *Eur J Cancer Prev* 2012; **21**: 308-315 [PMID: 22465911 DOI: 10.1097/CEJ.0b013e328351e1b6]

24 **de Koning HJ**, Meza R, Plevritis SK, ten Haaf K, Munshi VN, Jeon J, Erdogan SA, Kong CY, Han SS, van Rosmalen J, Choi SE, Pinsky PF, Berrington de Gonzalez A, Berg CD, Black WC, Tammemägi MC, Hazelton WD, Feuer EJ, McMahon PM. Benefits and harms of computed tomography lung cancer screening strategies: a comparative modeling study for the U.S. Preventive Services Task Force. *Ann Intern Med* 2014; **160**: 311-320 [PMID: 24379002 DOI: 10.7326/M13-2316]

25 **American Lung Association**. Providing guidance on lung cancer screening to patients and physicians. [accessed 2015 Sept]. Available from: URL: http//www.lung.org/lung-disease/lung- cancer/lung-cancer-screening-guidelines

26 **Tammemägi MC**, Katki HA, Hocking WG, Church TR, Caporaso N, Kvale PA, Chaturvedi AK, Silvestri GA, Riley TL, Commins J, Berg CD. Selection criteria for lung-cancer screening. *N Engl J Med* 2013; **368**: 728-736 [PMID: 23425165 DOI: 10.1056/NEJMoa1211776]

27 **Detterbeck FC**, Mazzone PJ, Naidich DP, Bach PB. Screening for lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest* 2013; **143**: e78S-e92S [PMID: 23649455 DOI: 10.1378/chest.12-2350]

28 **Bach PB**, Mirkin JN, Oliver TK, Azzoli CG, Berry DA, Brawley OW, Byers T, Colditz GA, Gould MK, Jett JR, Sabichi AL, Smith-Bindman R, Wood DE, Qaseem A, Detterbeck FC. Benefits and harms of CT screening for lung cancer: a systematic review. *JAMA* 2012; **307**: 2418-2429 [PMID: 22610500 DOI: 10.1001/jama.2012.5521]

29 **Centers for Medicare & Medicaid Services**. Final National Coverage Determination on Screening for Lung Cancer with Low Dose Computed Tomography (LDCT) (CAG-00439N). [accessed 2015 Mar]. Available from: URL: http//www.cms.gov/medicare-coverage-database/details/nca- decision-memo.aspx?NCAId=274

30 **Manser R**, Lethaby A, Irving LB, Stone C, Byrnes G, Abramson MJ, Campbell D. Screening for lung cancer. Cochrane Database Syst Rev, 2013

31 **Prosch H**, Schaefer-Prokop C. Screening for lung cancer. *Curr Opin Oncol* 2014; **26**: 131-137 [PMID: 24441507 DOI: 10.1097/CCO.0000000000000055]

32 **National Comprehensive Cancer Network**. Clinical Practice Guidelines in Oncology, Lung cancer screening: Version 2. [accessed 2015 Sept]. Available from: URL: http//www.nccn.org

33 **Jaklitsch MT**, Jacobson FL, Austin JH, Field JK, Jett JR, Keshavjee S, MacMahon H, Mulshine JL, Munden RF, Salgia R, Strauss GM, Swanson SJ, Travis WD, Sugarbaker DJ. The American Association for Thoracic Surgery guidelines for lung cancer screening using low-dose computed tomography scans for lung cancer survivors and other high-risk groups. *J Thorac Cardiovasc Surg* 2012; **144**: 33-38 [PMID: 22710039 DOI: 10.1016/j.jtcvs.2012.05.060]

34 **Hattori A**, Suzuki K, Aokage K, Mimae T, Nagai K, Tsuboi M, Okada M. Prognosis of lung cancer patients with a past history of colorectal cancer. *Jpn J Clin Oncol* 2014; **44**: 1088-1095 [PMID: 25156681 DOI: 10.1093/jjco/hyu122]

35 **Kovalchik SA**, Tammemagi M, Berg CD, Caporaso NE, Riley TL, Korch M, Silvestri GA, Chaturvedi AK, Katki HA. Targeting of low-dose CT screening according to the risk of lung-cancer death. *N Engl J Med* 2013; **369**: 245-254 [PMID: 23863051 DOI: 10.1056/NEJMoa1301851]

36 **Smetana GW**, Boiselle PM, Schwartzstein RM. Screening for lung cancer with low-dose computed tomography: grand rounds discussion from the Beth Israel Deaconess Medical Center. *Ann Intern Med* 2015; **162**: 577-582 [PMID: 25894026 DOI: 10.7326/M15-0055]

37 **Tammemägi MC**, Church TR, Hocking WG, Silvestri GA, Kvale PA, Riley TL, Commins J, Berg CD. Evaluation of the lung cancer risks at which to screen ever- and never-smokers: screening rules applied to the PLCO and NLST cohorts. *PLoS Med* 2014; **11**: e1001764 [PMID: 25460915 DOI: 10.1371/journal.pmed.1001764]

38 **Lou F**, Huang J, Sima CS, Dycoco J, Rusch V, Bach PB. Patterns of recurrence and second primary lung cancer in early-stage lung cancer survivors followed with routine computed tomography surveillance. *J Thorac Cardiovasc Surg* 2013; **145**: 75-81; discussion 81-2 [PMID: 23127371 DOI: 10.1016/j.jtcvs.2012.09.030]

39 **Griffioen GH**, Lagerwaard FJ, Haasbeek CJ, Slotman BJ, Senan S. A brief report on outcomes of stereotactic ablative radiotherapy for a second primary lung cancer: evidence in support of routine CT surveillance. *J Thorac Oncol* 2014; **9**: 1222-1225 [PMID: 25157777 DOI: 10.1097/JTO.0000000000000218]

40 **Hanna WC**, Keshavjee S. How to follow up patients after curative resection of lung cancer. *Semin Thorac Cardiovasc Surg* 2013; **25**: 213-217 [PMID: 24331143 DOI: 10.1053/j.semtcvs.2013.07.005]

41 **Surapaneni R**, Singh P, Rajagopalan K, Hageboutros A. Stage I lung cancer survivorship: risk of second malignancies and need for individualized care plan. *J Thorac Oncol* 2012; **7**: 1252-1256 [PMID: 22627646 DOI: 10.1097/JTO.0b013e3182582a79]

42 **Pepek JM**, Chino JP, Marks LB, D'amico TA, Yoo DS, Onaitis MW, Ready NE, Hubbs JL, Boyd J, Kelsey CR. How well does the new lung cancer staging system predict for local/regional recurrence after surgery?: A comparison of the TNM 6 and 7 systems. *J Thorac Oncol* 2011; **6**: 757-761 [PMID: 21325975 DOI: 10.1097/JTO.0b013e31821038c0]

43 **Choi PJ**, Jeong SS, Yoon SS. Prognosis of recurrence after complete resection in early-stage non-small cell lung cancer. *Korean J Thorac Cardiovasc Surg* 2013; **46**: 449-456 [PMID: 24368972 DOI: 10.5090/kjtcs.2013.46.6.449]

44 **Mollberg NM**, Ferguson MK. Postoperative surveillance for non-small cell lung cancer resected with curative intent: developing a patient-centered approach. *Ann Thorac Surg* 2013; **95**: 1112-1121 [PMID: 23352418 DOI: 10.1016/j.athoracsur.2012.09.075]

45 **Crabtree TD**, Puri V, Chen SB, Gierada DS, Bell JM, Broderick S, Krupnick AS, Kreisel D, Patterson GA, Meyers BF. Does the method of radiologic surveillance affect survival after resection of stage I non-small cell lung cancer? *J Thorac Cardiovasc Surg* 2015; **149**: 45-52, 53.e1-3 [PMID: 25218540 DOI: 10.1016/j.jtcvs.2014.07.095]

46 **Benamore R**, Shepherd FA, Leighl N, Pintilie M, Patel M, Feld R, Herman S. Does intensive follow-up alter outcome in patients with advanced lung cancer? *J Thorac Oncol* 2007; **2**: 273-281 [PMID: 17409797 DOI: 10.1097/01.JTO.0000263708.08332.76]

47 **Westeel V**, Lebitasy MP, Mercier M, Girard P, Barlesi F, Blanchon F, Tredaniel J, Bonnette P, Woronoff-Lemsi MC, Breton JL, Azarian R, Falcoz PE, Friard S, Geriniere L, Laporte S, Lemarie E, Quoix E, Zalcman G, Guigay J, Morin F, Milleron B, Depierre A. [IFCT-0302 trial: randomised study comparing two follow-up schedules in completely resected non-small cell lung cancer]. *Rev Mal Respir* 2007; **24**: 645-652 [PMID: 17519819 DOI: RMR-05-2007-24-5-0761-8425-101019-20064112]

48 **Parsons A**, Daley A, Begh R, Aveyard P. Influence of smoking cessation after diagnosis of early stage lung cancer on prognosis: systematic review of observational studies with meta-analysis. *BMJ* 2010; **340**: b5569 [PMID: 20093278 DOI: 10.1136/bmj.b5569]

49 **Sardari Nia P**, Weyler J, Colpaert C, Vermeulen P, Van Marck E, Van Schil P. Prognostic value of smoking status in operated non-small cell lung cancer. *Lung Cancer* 2005; **47**: 351-359 [PMID: 15713518 DOI: 10.1016/j.lungcan.2004.08.011]

50 **Milano MT**, Peterson CR, Zhang H, Singh DP, Chen Y. Second primary lung cancer after head and neck squamous cell cancer: population-based study of risk factors. *Head Neck* 2012; **34**: 1782-1788 [PMID: 22319019 DOI: 10.1002/hed.22006]

51 **Baxi SS**, Pinheiro LC, Patil SM, Pfister DG, Oeffinger KC, Elkin EB. Causes of death in long-term survivors of head and neck cancer. *Cancer* 2014; **120**: 1507-1513 [PMID: 24863390 DOI: 10.1002/cncr.28588]

52 **Wolff HA**, Wolff CR, Hess CF, Jung K, Sennhenn-Kirchner S, Hinterthaner M, Müller-Dornieden A, Körber W, Marten-Engelke K, Roedel R, Christiansen H, Engelke C. Second primary malignancies in head and neck cancer patients: high prevalence of curable-stage disease. *Strahlenther Onkol* 2013; **189**: 874-880 [PMID: 23842636 DOI: 10.1007/s00066-013-0404-4]

53 **Madana J**, Morand GB, Barona-Lleo L, Black MJ, Mlynarek AM, Hier MP. A survey on pulmonary screening practices among otolaryngology-head & amp; neck surgeons across Canada in the post treatment surveillance of head and neck squamous cell carcinoma. *J Otolaryngol Head Neck Surg* 2015; **44**: 5 [PMID: 25649793 DOI: 10.1186/s40463-015-0057-7]

54 **Pagedar NA**, Jayawardena A, Charlton ME, Hoffman HT. Second Primary Lung Cancer After Head and Neck Cancer: Implications for Screening Computed Tomography. *Ann Otol Rhinol Laryngol* 2015; **124**: 765-769 [PMID: 25881583 DOI: 10.1177/0003489415582259]

55 **Geurts TW**, Balm AJ, van Velthuysen ML, van Tinteren H, Burgers JA, van Zandwijk N, Klomp HM. Survival after surgical resection of pulmonary metastases and second primary squamous cell lung carcinomas in head and neck cancer. *Head Neck* 2009; **31**: 220-226 [PMID: 18972427 DOI: 10.1002/hed.20952]

56 **Griffioen GH**, Louie AV, de Bree R, Smit EF, Paul MA, Slotman BJ, Leemans CR, Senan S. Second primary lung cancers following a diagnosis of primary head and neck cancer. *Lung Cancer* 2015; **88**: 94-99 [PMID: 25662386 DOI: 10.1016/j.lungcan.2015.01.011]

57 **Atabek U**, Mohit-Tabatabai MA, Raina S, Rush BF, Dasmahapatra KS. Lung cancer in patients with head and neck cancer. Incidence and long-term survival. *Am J Surg* 1987; **154**: 434-438 [PMID: 3661848 DOI: 10.1016/0002-9610(89)90019-6]

58 **Margolis ML**, Howlett P, Bubanj R. Pulmonary nodules in patients with esophageal carcinoma. *J Clin Gastroenterol* 1998; **26**: 245-248 [PMID: 9649002]

59 **Kim JW**, Jang JY, Chang YW, Kim YH. Clinical features of second primary cancers arising in early gastric cancer patients after endoscopic resection. *World J Gastroenterol* 2015; **21**: 8358-8365 [PMID: 26217087 DOI: 10.3748/wjg.v21.i27.8358]

60 **Khatcheressian JL**, Hurley P, Bantug E, Esserman LJ, Grunfeld E, Halberg F, Hantel A, Henry NL, Muss HB, Smith TJ, Vogel VG, Wolff AC, Somerfield MR, Davidson NE. Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update. *J Clin Oncol* 2013; **31**: 961-965 [PMID: 23129741 DOI: 10.1200/JCO.2012.45.9859]

61 **Smith TJ**. Breast cancer surveillance guidelines. *J Oncol Pract* 2013; **9**: 65-67 [PMID: 23633975 DOI: 10.1200/JOP.2012.000787]

62 **James JJ**, McMahon MA, Tennant SL, Cornford EJ. CT staging for breast cancer patients with poor prognostic tumours. *Breast* 2012; **21**: 735-738 [PMID: 22959310 DOI: 10.1016/j.breast.2012.08.001]

63 **Kitada M**, Sato K, Matsuda Y, Hayashi S, Miyokawa N, Sasajima T. Role of treatment for solitary pulmonary nodule in breast cancer patients. *World J Surg Oncol* 2011; **9**: 124 [PMID: 21989021 DOI: 10.1186/1477-7819-9-124]

64 **Grantzau T**, Overgaard J. Risk of second non-breast cancer after radiotherapy for breast cancer: a systematic review and meta-analysis of 762,468 patients. *Radiother Oncol* 2015; **114**: 56-65 [PMID: 25454172 DOI: 10.1016/j.radonc.2014.10.004]

65 **Kirova YM**, De Rycke Y, Gambotti L, Pierga JY, Asselain B, Fourquet A. Second malignancies after breast cancer: the impact of different treatment modalities. *Br J Cancer* 2008; **98**: 870-874 [PMID: 18268495 DOI: 10.1038/sj.bjc.6604241]

66 **Grantzau T**, Thomsen MS, Vaeth M, Overgaard J. Risk of second primary lung cancer in women after radiotherapy for breast cancer. *Radiother Oncol* 2014; **111**: 366-373 [DOI: 10.1016/j.radonc.2014.05.004]

67 **Kerendi F**, Gal A, Corvera JS, Halkos ME, Miller JI. Characteristics of second primary lung malignancy in patients with known breast cancer. *South Med J* 2009; **102**: 269-274 [PMID: 19204611 DOI: 10.1097/SMJ.0b013e318197fec6]

68 **Milano MT**, Strawderman RL, Venigalla S, Ng K, Travis LB. Non-small-cell lung cancer after breast cancer: a population-based study of clinicopathologic characteristics and survival outcomes in 3529 women. *J Thorac Oncol* 2014; **9**: 1081-1090 [PMID: 25157761 DOI: 10.1097/JTO.0000000000000213]

69 **Tanaka K**, Shimizu K, Ohtaki Y, Nakano T, Kamiyoshihara M, Kaira K, Rokutanda N, Horiguchi J, Oyama T, Takeyoshi I. Diagnosis and surgical resection of solitary pulmonary nodules in patients with breast cancer. *Mol Clin Oncol* 2013; **1**: 117-123 [PMID: 24649133 DOI: 10.3892/mco.2012.21]

70 **Kinoshita T**, Yoshida J, Ishii G, Hishida T, Wada M, Aokage K, Nagai K. The availability of pre- and intraoperative evaluation of a solitary pulmonary nodule in breast cancer patients. *Ann Thorac Cardiovasc Surg* 2015; **21**: 31-36 [PMID: 24835922 DOI: 10.5761/atcs.oa.14-00025]

71 **Friedel G**, Pastorino U, Ginsberg RJ, Goldstraw P, Johnston M, Pass H, Putnam JB, Toomes H. Results of lung metastasectomy from breast cancer: prognostic criteria on the basis of 467 cases of the International Registry of Lung Metastases. *Eur J Cardiothorac Surg* 2002; **22**: 335-344 [PMID: 12204720 DOI: 10.1016/S1010-7940(02)00331-7]

72 **del Rey J**, Placer J, Vallmanya F, Pujol N, Prat E, Miró R, Gelabert A. Are patients with non-muscle-invasive bladder cancer a suitable population for a lung cancer screening trial? *BJU Int* 2010; **106**: 49-52 [PMID: 19922541 DOI: 10.1111/j.1464-410X.2009.09081.x]

73 **Ng A**, Constine LS, Advani R, Das P, Flowers C, Friedberg J, Hodgson DC, Schwartz CL, Wilder RB, Wilson LD, Yunes MJ. ACR Appropriateness Criteria: follow-up of Hodgkin's lymphoma. *Curr Probl Cancer* 2010; **34**: 211-227 [PMID: 20541059 DOI: 10.1016/j.currproblcancer.2010.04.007]

74 **Ibrahim EM**, Kazkaz GA, Abouelkhair KM, Al-Mansour MM, Al-Fayea TM, Al-Foheidi M, Bayer AM, Elmasri OA. Increased risk of second lung cancer in Hodgkin's lymphoma survivors: a meta-analysis. *Lung* 2013; **191**: 117-134 [PMID: 23053567 DOI: 10.1007/s00408-012-9418-4]

75 **Das P**, Ng AK, Earle CC, Mauch PM, Kuntz KM. Computed tomography screening for lung cancer in Hodgkin's lymphoma survivors: decision analysis and cost-effectiveness analysis. *Ann Oncol* 2006; **17**: 785-793 [PMID: 16500905 DOI: 10.1093/annonc/mdl023]

76 **Wattson DA**, Hunink MG, DiPiro PJ, Das P, Hodgson DC, Mauch PM, Ng AK. Low-dose chest computed tomography for lung cancer screening among Hodgkin lymphoma survivors: a cost-effectiveness analysis. *Int J Radiat Oncol Biol Phys* 2014; **90**: 344-353 [PMID: 25104066 DOI: 10.1016/j.ijrobp.2014.06.013]

77 **Milano MT**, Li H, Constine LS, Travis LB. Survival after second primary lung cancer: a population-based study of 187 Hodgkin lymphoma patients. *Cancer* 2011; **117**: 5538-5547 [PMID: 21692074 DOI: 10.1002/cncr.26257]

78 **University Health Network Toronto**. Low dose chest CT for lung cancer screening in survivors of Hodgkin's disease. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000-2015. Available from: URL: http//clinicaltrials.gov/ct2/show/NCT01180010?term=lung cancer screening&rank=18 NLM Indentifier: NCT01180010

79 **Steele SR**, Chang GJ, Hendren S, Weiser M, Irani J, Buie WD, Rafferty JF. Practice Guideline for the Surveillance of Patients After Curative Treatment of Colon and Rectal Cancer. *Dis Colon Rectum* 2015; **58**: 713-725 [PMID: 26163950 DOI: 10.1097/DCR.0000000000000410]

80 **Pita-Fernández S**, Alhayek-Aí M, González-Martín C, López-Calviño B, Seoane-Pillado T, Pértega-Díaz S. Intensive follow-up strategies improve outcomes in nonmetastatic colorectal cancer patients after curative surgery: a systematic review and meta-analysis. *Ann Oncol* 2015; **26**: 644-656 [PMID: 25411419 DOI: 10.1093/annonc/mdu543]

81 **Lee YT**, Liu CJ, Hu YW, Teng CJ, Tzeng CH, Yeh CM, Chen TJ, Lin JK, Lin CC, Lan YT, Wang HS, Yang SH, Jiang JK, Chen WS, Lin TC, Chang SC, Chen MH, Teng HW, Liu JH, Yen CC. Incidence of Second Primary Malignancies Following Colorectal Cancer: A Distinct Pattern of Occurrence Between Colon and Rectal Cancers and Association of Co-Morbidity with Second Primary Malignancies in a Population-Based Cohort of 98,876 Patients in Taiwan. *Medicine* (Baltimore) 2015; **94**: e1079 [PMID: 26131831 DOI: 10.1097/MD.0000000000001079]

**P-Reviewer:** Garfield D, Kawai H, Sugawara I **S-Editor:** Qiu S **L-Editor: E-Editor:**

|  |
| --- |
| **Table 1 Index trials of lung cancer screening** |
| **Ref.** | **Participants** | **Exclusion criteria** | **Design** | **Results** |
| Aberle *et al*[5] | 53454 participants - age 55 to 74-at least 30 pack-year smoking history-former smokers must have quit within previous 15 years | Previous lung cancer diagnosisCT scan within previous 18 moHemoptysis or unexplained weight loss of 15 lbs or more in last year | Randomized Control TrialParticipants randomized to three annual screenings with LDCT (26,722) *vs* single view PA CXR (26732) | Rate of positive screening was 24.2% in LDCT and 6.9% with CXR group. The majority of positive screening results were false positives, 96.4% in the LDCT group and 94.5% in the CXR group. Lung cancer mortality decreased by 20% (*P* = 0.004) and all cause mortality decreased by 6.7% in LDCT group (*P* = 0.02). |
| van Iersel *et al*[14] | 15822 participants- age 50-74- determined to be high risk based on answers to heath questionnaire- good overall health (able to climb 2 flights of stairs, weight less than 140 kg) | Current or past diagnosis of renal cancer, melanoma or breast cancer Lung cancer diagnosis within last 5 years or current treatmentCT scan within past year  | Randomized Control TrialParticipants randomized to either LDCT screening (7915) or no screening (7907) | Ongoing- 10 year follow up planned |
| Infante*et al*[16] | 2472 participants- males aged 60-74- 20 pack-year smoking history  | History of previous malignancy treated within 10 years (exceptions: early laryngeal cancer and nonmelanoma skin cancer with a 5-year disease-free interval)Comorbid conditions with life expectancy less than 5 years | Randomized Control Trial Randomized to five years of annual screening with LDCT (1276) or clinical follow up (1196)  | Ongoing. 3 yr results: Lung cancer detected in 4.7% of patients in LDCT group and 2.8% in controls (*P* = 0.016) There was a 1.6% lung cancer mortality in the LDCT group and 1.7% in the control group (*P* = 0.84). No difference in all cause mortality (*P* = 0.83) to this point in the studyThere was a higher rate of invasive procedures performed in the LDCT group compared with controls (*P* < 0.0001) |
| Saghir *et al*[22] | 4104 participants- age 50-70- at least 20 pack-year smoking history- former smokers who quit after age 50 and quit less than 10 years prior- FEV1 of at least 30% predicted value - Good overall health (able to climb 2 flights of stairs, weight less than 130 kg)  | Previous cancer diagnosis and treatmentComorbid illness that would shorten life expectancy to < 10 years CT scan within previous year  | Randomized control trialParticipants randomized to five annual LDCT screenings (2052) or no screening (2052) | Ongoing. 5 year results:Lung cancer was diagnosed in 69 patients in the LDCT group, compared with 24 in the control group (*P* < 0.001)Stage I-IIB lung cancer was diagnosed more frequently in the LDCT group (*P* = 0.002), however there was no difference in frequency of Stage IIIA-IV lung cancer (*P* = 0.509)There was no difference in mortality from lung cancer (*P* = 0.428) or overall mortality (*P* = 0.059) to this point of follow up |
| Pastorino *et al*[23] | 4099 participants - age 49 or older- at least 20 pack-year smoking history - current smoker or had quit within 10 years  | History of cancer within the previous 5 years | Randomized Control Trial Randomized participants to annual LDCT screening (1,190), biennial LDCT screening (1186), or observation alone (1723) | The cumulative 5-yr lung cancer incidence rate was 0.0031% in the control group, 0.0046% in the biennial, and 0.0062% in the annual LDCT group (*P* = 0.036)Rates of mortality from lung cancer were 0.0011% in the control group, 0.0011% in the biennial group, and 0.0022% in the annual group (*P* = 0.21). There was also no difference in all cause mortality between the three groups (*P* = 0.13).  |

LDCT: Low dose CT; CXR: Chest radiography; CT: Computed tomography.

|  |
| --- |
| **Table 2 Prior malignancy and lung cancer** |
| **Prior malignancy** | **Study****Ref. Method** | **Results** |
| Lung  | Lou *et al*[38] | 1294 participants with early-stage NSCLC underwent resection and then were followed with surveillance CT screening | Recurrence was diagnosed in 20% of patients and second primary lung cancer was diagnosed 7% of patients. The risk of second primary lung cancer diagnosis did not decrease over timeOf the second primary cancers that were diagnosed, 93% were identified by scheduled surveillance CT. Of the recurrences that were diagnosed, 61% were identified by surveillance CT. Twenty five percent of patients required additional invasive testing, but less than 1% experienced complications from these procedures |
| Head and Neck  | Mila *et al*[50] | 61,883 patients with SCC of the head and neck were identified *via* the SEER database. Of those, 4522 developed a second primary lung cancer. A retrospective data analysis was performed | The risk of developing a primary lung cancer after HNSCC was 5.8%, 11.4%, and 16.4% at 5, 10, and 15 yearsThese rates are higher compared to the general population |
| Head and Neck  | Baxi *et al*[51] | 35958 three-year survivors of SCC of the head and neck were identified *via* SEER database. A competing-risks proportional hazards regression was used to estimate probabilities of death from different causes | Second primary malignancy was the second leading cause of death (second only to primary head and neck squamous cell carcinoma) in this populationOf these, 53% of second primary malignancies were lung cancer  |
| Head and Neck  | Pagedar *et al*[54] | Data was collected and retrospectively analyzed. Survival estimates were generated for patients with lung cancer with and without a history of head and neck cancer | The median survival of patients with only primary lung cancer was 38 mo, compared to 22 mo in those with a history of head and neck cancer with lung cancer as a second primary malignancy. This statistically significant difference suggests that survival outcomes after lung cancer diagnosis are worse in patients who have a history of head and neck malignancy |
| Breast | Kitada *et al*[63] | Data was collected an analyzed on 1226 patients who underwent surgical resection of breast cancer, 49 of whom were found to have at lease one pulmonary lesion during or after workup | 14 patients underwent surgical resection of the pulmonary lesion. Primary lung cancer was the diagnoses in 3 of these patients, metastases in 8 cases. Of those diagnosed with second primary lung cancer, the stage was IA in all |
| Breast  | Kerendi *et al*[67] | 35 patients with breast cancer and second primary lung cancer were identified and retrospective analysis of survival was performed | More than half of patients had their lung cancer diagnosed during workup or follow-up. 54% of these patients were successfully treated with surgery. There was a statistically significant survival benefit when the cancer was detected early (stage 1A, asymptomatic)  |
| Breast | Milano *et al*[68] | 3529 women with NSCLC diagnosis after breast treatment were identified in the SEER database. Data on these patients was retrospectively analyzed and compared to data on 151,628 women diagnosed with NSCLC alone | Patients with a history of breast cancer were diagnosed at significant earlier stage, although surgical resection was used more frequently in the NSCLC only group. History of breast cancer history did not affect overall survival in localized NSCLC. Overall survival was significantly greater in patients with regional and distant NSCLC that had a history of breast cancer |
| Bladder | Del Rey *et al*[72] | Data from 231 patients with non-muscle invasive bladder cancer were retrospectively analyzed | Lung cancer was the most common second primary malignancy in this population. The risk of lung cancer in patients with non-muscle invasive bladder cancer is 10 fold higher than the regional general population |
| Lymphoma | Das *et al*[75]  | Authors used a decision-analytic model to estimate potential benefits of annual low-dose CT screening *vs* no screening in a hypothetical cohort of patients (early stage lymphoma diagnosed at age 25, lung cancer screening starting at age 30). Model parameters were generated from SEER | In this simulated model, annual CT screening increased survival by 0.64 years for smokers and 0.16 years for non-smokers. The difference in quality of life and cost effectiveness was also more pronounced in smokers |
| Lymphoma | Milano *et al*[77] | Survival data of 187 patient with history of Hodgkins Lymphoma diagnosed with NSCLC was compated to data from 178, 431 patients diagnosed with NSCLC only | Hodgkins lymphoma survivors had significantly inferior overall survival across all lung cancer stages (estimated to be between 30% to 60% decrease in overall survival)Patients with younger age at lymphoma diagnosis, younger age at lung cancer diagnoses, and those with longer latency between cancer diagnoses were more likely to be diagnosed with late stage disease |
| Colorectal | Hattori *et al*[82] | A retrospective analysis of lung cancer patients with (123) or without (4431) a previous history of colorectal cancer treated with surgical resection.  | There is no statistically significant difference in overall survival comparing patients with lung cancer *vs* lung cancer with a history of surgery for colorectal cancer. Prior history of colorectal cancer was not a poor prognostic indicator on multivariate analysisOf those patients who had been diagnosed with both lung and colorectal cancer, those who are older and those who underwent treatment with adjuvant chemotherapy had poorer outcomes |

CT: Computed tomography; NSCLC: Non-small-cell lung cancer; SEER: Surveillance, epidemiology and end results; SCC: Squamous cell cancer; HNSCC: Head and neck squamous cell cancer.